Information Provided By:
Fly News Breaks for October 17, 2019
ALV, CRUS, SAM, TEVA, TCS
Oct 17, 2019 | 10:10 EDT
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Container Store (TCS) upgraded to Neutral from Sell at Goldman Sachs with analyst Kate McShane saying after the recent underperformance, the she sees less downside risk for Container Store shares. 2. Teva (TEVA) upgraded to Buy from Hold at Gabelli with analyst Kevin Kedra citing reports that the company had proposed to settle its opioid litigation by giving away $15B of free drugs. 3. Boston Beer (SAM) upgraded to Outperform from Market Perform at Cowen with analyst Vivien Azer saying with Truly continuing to drive "outsized growth," and with new formulations and a lemonade line-extension slated for next year, the brand will continue to transform Boston Beer's "growth algorithm" and offset continued softness in beer and cider. 4. Cirrus Logic (CRUS) upgraded to Equal Weight from Underweight at Barclays analyst Blayne Curtis saying he no longer sees a downside catalyst and risk to consensus estimates. 5. Autoliv (ALV) upgraded to In Line from Underperform at Evercore ISI with analyst Chris McNally citing seasonality, the company's upcoming Capital Markets Day and as he rolled forward his auto supplier targets to 2021. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
News For TCS;TEVA;SAM;CRUS;ALV From the Last 2 Days
TEVA
Apr 19, 2021 | 09:24 EDT
73rd Annual Virtual Meeting of AAN will be held on April 17-22. Webcast Link
TEVA
Apr 19, 2021 | 08:17 EDT
Teva Pharmaceuticals announced new data from clinical and real-world analyses examining the efficacy of AJOVY. These data are being presented at the 2021 American Academy of Neurology (AAN) Virtual Annual Meeting, taking place April 17-22. The data being presented at the meeting span 17 posters and include post-hoc Phase 3 data examining the long-term response of AJOVY in patients who initially did not respond to treatment, an analysis of real-world treatment patterns for patients prescribed AJOVY, and a retrospective evaluation of quarterly and monthly dosing with AJOVY in a real-world setting. "In addition to our continued work evaluating Phase 3 AJOVY data, we now look forward to studying AJOVY in a real-world setting using patient data and outcomes to help validate our clinical trial findings and advance the AJOVY patient experience," said Denisa Hurtukova, MD, VP, Head of North America Medical Affairs. "The data presented at AAN provide valuable insights into the long-term use of AJOVY in both clinical and real-world settings, giving the migraine community valuable information and a broader understanding of the potential efficacy of ongoing treatment."